Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,683.90
(
0.00%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 237723

Monday, 03/27/2023 9:55:51 AM

Monday, March 27, 2023 9:55:51 AM

Post# of 257484
PFE returns Bavencio commercial rights to Merck KGaA in return for 15% royalty on sales:

https://www.emdgroup.com/en/news/oncology-27-03-2023.html

PFE booked $271M in Bavencio alliance revenue in 2022, which is a pretty small amount for a PD-(L)1 drug. Moreover, PFE has a subcutaneous PD-1, Sasanlimab, in its wholly-owned pipeline (#msg-163133643).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today